| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5891936 | Bone | 2012 | 7 Pages |
Abstract
âºGlucocorticoid osteoporosis (GIO) is common but whether there are gender differences in response to therapy is unknown. âºExamined benefits of zoledronate and risedronate in male patients with GIO. âºSingle zoledronate infusion superior to risedronate in effects on BMD at most skeletal sites and bone turnover. âºEffect seen in both prevention and treatments arms.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Philip N. Sambrook, Christian Roux, Jean-Pierre Devogelaer, Kenneth Saag, Chak-Sing Lau, Jean-Yves Reginster, Christina Bucci-Rechtweg, Guoqin Su, David M. Reid,